NCT07021430View on ClinicalTrials.gov

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Malaria Prevention
Interventions
DRUG

Dihydroartemisinin Piperaquine

A single or monthly dose of Dihydroartemisinin Piperaquine based on weight will be taken orally.

Trial Locations (1)

Unknown

Bugoye Level III Health Center, Kasese

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of North Carolina, Chapel Hill

OTHER